Sydney M Crago

Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Theodore Lang, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Srinivas Sai Kondapalli, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the predictive role of outer retinal tubulations in lesion growth for subfoveal and non subfoveal geographic atrophy at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Attendees shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

Data can clear a path to trends and strategies to meet patients’ needs

In a conversation with the Eye Care Network at ARVO, Osamah Saeedi, MD, MS, Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine, explained the key findings from his poster.

More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia

Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations at the ARVO annual conference in Seattle, Washington.

The 3 participants have also received their first aflibercept injection for the treatment of wet AMD.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

The GLYCO Phase 2 US clinical trial will evaluate AVD-104 for the management of diabetic macular edema (DME).

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

Catch up on a few of Modern Retina's top stories and ones you may have missed in 2023

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for diabetic macular edema.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD.

The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.

Eyecare providers report slower Q3 and increased concern for the US economy and inflation rates.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.